Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
Recruiting now · Not applicable
Conditions studied: Hematologic Diseases
In brief
The purpose of the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy. Initially this device will be used in a single-center, open-label, single-arm, phase II clinical trial to evaluate the efficacy of haploidentical PBSC grafts depleted of TCRα/β+ and CD19+ cells using the CliniMACS® TCRαβ/CD19 System in children and adults with hematological and non-hematological malignancies.
Key facts
- Study ID
- NCT04249830
- Run by
- Alice Bertaina
- People needed
- 204
- Starts
- 2020-02-01
- Expected to finish
- 2030-12-01
- Last updated by the study team
- 2025-05-29
Who can join
Age: 0 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lucile Packard Children's Hospital — Palo Alto, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.